Dr. Wassim Abida, MD, PhD

Dr. Abida practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Abida's NPI, 1518101096, was assigned on April 28, 2009. Dr. Abida graduated from Columbia University Vagelos College of Physicians and Surgeons in 2009. Dr. Abida holds New York license 260102-1.

Dr. Abida's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Abida's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Abida to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abida practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Abida's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Abida's licenses on file in 2 states: New York and Pennsylvania.

CMS data shows 535 Medicare services from Dr. Abida across 3 procedure codes in 2024, all of them office visits, for 188 Medicare patients. Medicare paid $47,061 for them. Every service was in an office.

CMS counts 188 Medicare patients who saw Dr. Abida in 2024. The largest group is 75 to 84, with 89 patients. 75% of them have cancer, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abida's median patient age at 76, with 2% women.

In 2024, Dr. Abida wrote 836 Medicare Part D claims for 112 patients. 66% of them were for generic drugs. CMS names the drug for 734 of them, across 9 drugs with 11 or more claims each, at $3,397,455 in total drug cost. In 2023, CMS named 685 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Abida for performance year 2024, reported as part of a group. Dr. Abida accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abida as offering telehealth.

Dmand AI links 82 papers to Dr. Abida, published from 2014 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms and Biomarkers, Tumor. Dr. Abida has published most often in Clin Cancer Res. Dr. Abida's most frequent co-authors are Howard I. Scher, MD, Philip W. Kantoff, MD and Mark E. Robson, MD.

Dmand AI links Dr. Abida to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Neoplasm Metastasis.

CMS Open Payments shows 36 general payments to Dr. Abida from 9 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 66% of the total. Pfizer Inc. paid the most, $5,700. It also lists 4 research payments totaling $570 from 2017 to 2018.

Dr. Abida graduated from Columbia University Vagelos College of Physicians and Surgeons in 2009.